CEO
Vincent Angotti
Employees
46
Industry
Pharmaceutical Preparation Manufacturing
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Loading...
Open
0.78
Mkt cap
15M
Volume
241K
High
0.88
P/E Ratio
-0.31
52-wk high
2.30
Low
0.78
Div yield
N/A
52-wk low
0.42
Portfolio Pulse from Benzinga Insights
October 24, 2023 | 9:31 pm
Portfolio Pulse from Benzinga Insights
October 23, 2023 | 1:06 pm
Portfolio Pulse from Benzinga Newsdesk
October 20, 2023 | 8:35 pm
Portfolio Pulse from Benzinga Insights
October 09, 2023 | 1:06 pm
Portfolio Pulse from Bill Haddad
October 03, 2023 | 12:31 pm
Portfolio Pulse from Benzinga Newsdesk
October 02, 2023 | 12:28 pm
Portfolio Pulse from Benzinga Insights
September 25, 2023 | 1:06 pm
Portfolio Pulse from Benzinga Newsdesk
September 25, 2023 | 10:19 am
Portfolio Pulse from Benzinga Insights
August 18, 2023 | 1:06 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.